Dr. Kwon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Lakeside Dr
Foster City, CA 94404Phone+1 650-617-3200
Education & Training
University of California (San Francisco)Residency, Dermatology, 1997 - 2000
Kaiser Permanente Northern California (Oakland)Internship, Internal Medicine, 1996 - 1997- University of California San Francisco School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 1998 - 2026- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
Publications & Presentations
PubMed
- 17 citationsValidation of psychometric properties of the itch numeric rating scale for pruritus associated with prurigo nodularis: a secondary analysis of a randomized clinical trialMiriam Kimel, Claudia Zeidler, Paul Kwon, Dennis A. Revicki, Sonja Ständer
JAMA Dermatology. 2020-12-01 - 29 citationsPhase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trialAlbert S. Chiou, Sara Choi, M. Barriga, Yana Dutt-Singkh, Daniel Solis
Journal of the American Academy of Dermatology. 2020-06-01 - 77 citationsSerlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.Sonja Ständer, Paul Kwon, Joe Hirman, Andrew J. Perlman, Elke Weisshaar
Journal of the American Academy of Dermatology. 2019-05-01
Press Mentions
Serlopitant’s Potential to Manage Itch in EB Patients Shown in Exploratory TrialJune 6th, 2018
Stanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant TreatmentMay 21st, 2018
Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of DermatologyFebruary 20th, 2018- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
